Osiris Therapeutics Stock Price, News & Analysis (OTCMKTS:OSIR)

$5.60 0.10 (1.82 %)
(As of 12/12/2017 08:54 AM ET)
Previous Close$5.50
Today's Range$5.50 - $5.60
52-Week Range$2.67 - $7.15
Volume8,455 shs
Average Volume14,894 shs
Market Capitalization$189.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84

About Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Receive OSIR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:OSIR
CUSIP68827R10
Phone443-545-1800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$59.87 million
Price / Sales3.23
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares34,530,000

Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

Who are some of Osiris Therapeutics' key competitors?

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the folowing people:

  • Peter Friedli, Chairman of the Board (Age 62)
  • Jason Keefer, Interim President, Chief Executive Officer, Vice President of Marketing (Age 45)
  • Linda Palczuk, President, Chief Executive Officer (Age 55)
  • Linda L. Chang, Chief Financial Officer (Age 51)
  • Frank D. Czworka Jr., Vice President, General Manager of Wound Care (Age 46)
  • Adrian P. Mollo, General Counsel (Age 41)
  • Alla N. Danilkovitch Ph.D., Chief Scientific Officer (Age 51)
  • Thomas M. Brandt Jr., Independent Director (Age 63)
  • Thomas J. Knapp, Independent Director (Age 63)
  • Jay M. Moyes, Independent Director (Age 63)

How do I buy Osiris Therapeutics stock?

Shares of Osiris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of Osiris Therapeutics stock can currently be purchased for approximately $5.60.

How big of a company is Osiris Therapeutics?

Osiris Therapeutics has a market capitalization of $189.89 million and generates $59.87 million in revenue each year.

How can I contact Osiris Therapeutics?

Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]


MarketBeat Community Rating for Osiris Therapeutics (OSIR)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Osiris Therapeutics (OTCMKTS:OSIR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ASellHold
Consensus Rating Score: N/AN/A1.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$4.00$4.00
Price Target Upside: N/AN/A17.70% downside17.70% downside

Osiris Therapeutics (OTCMKTS:OSIR) Consensus Price Target History

Price Target History for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS:OSIR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/16/2016Brean CapitalReiterated RatingSell$4.00View Rating Details
2/2/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Osiris Therapeutics (OTCMKTS:OSIR) Earnings History and Estimates Chart

Earnings by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS OSIR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
5/12/2014($0.08)($0.02)$9.00 million$10.05 millionViewN/AView Earnings Details
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Osiris Therapeutics (OTCMKTS:OSIR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Osiris Therapeutics (OTCMKTS:OSIR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2015special$0.209/14/20159/16/20159/30/2015
9/17/2015special$0.2010/14/201510/16/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Osiris Therapeutics (OTCMKTS OSIR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 0.27%
Insider Trades by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)
Institutional Ownership by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS OSIR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.21View SEC Filing  
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.28View SEC Filing  
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Osiris Therapeutics (OTCMKTS OSIR) News Headlines

Source:

SEC Filings

Osiris Therapeutics (OTCMKTS:OSIR) SEC Filings

DateFilerForm TypeView
12/05/2017
3:01 PM
Osiris Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing

Social Media

Financials

Osiris Therapeutics (OTCMKTS:OSIR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Osiris Therapeutics (OTCMKTS OSIR) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.